Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer

Biomedicine and Pharmacotherapy

Volumn 84, Issue , 2016, Pages 592-600

  Mahdian shakib, Ahmad ^a   Dorostkar, Ruhollah ^b   Tat, Mahdi ^b   Hashemzadeh, Mohammad Sadegh ^b   Saidi, Navid ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHED UNIVERSITY   (Iran)

Author keywords

Diagnosis; miRNA; Ovarian cancer; Prognosis

Indexed keywords

BETA CATENIN; BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CISPLATIN; CYCLOSPORIN A; EPIDERMAL GROWTH FACTOR RECEPTOR; GENE THERAPY AGENT; LYMPHOID ENHANCER FACTOR 1; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MICRORNA; MICRORNA 141; MICRORNA 200A; MICRORNA 200C; MICRORNA 21; MICRORNA 214; MICRORNA 22; MICRORNA 221; MICRORNA 223; MICRORNA 9; MRX 34; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN KINASE B; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; TUMOR MARKER;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENESIS; CELL INVASION; CELL PROLIFERATION; DOWN REGULATION; GENE EXPRESSION PROFILING; HUMAN; LONG TERM SURVIVAL; METASTASIS; MORTALITY RATE; NEOPLASM; OVARY CANCER; OVARY CARCINOMA; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; UPREGULATION; ANIMAL; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; METABOLISM; MOLECULAR DIAGNOSIS; OVARIAN NEOPLASMS; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HUMANS; MICRORNAS; MOLECULAR DIAGNOSTIC TECHNIQUES; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 84988911811     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.09.087     Document Type: Review

References (101)

1. [1] Siegel, R., Naishadham, D., Jemal, A., Cancer statistics 2012. CA. Cancer J. Clin. 62 (2012), 10–29.
2. [2] Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., et al. Cancer statistics 2008. CA. Cancer J. Clin. 58 (2008), 71–96.
3. [3] Di Leva, G., Croce, C.M., miRNA profiling of cancer. Curr. Opin. Genet. Dev. 23 (2013), 3–11.
4. [4] Prat, J., Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int. J. Gynecol. Obstet. 124 (2014), 1–5.
5. [5] van Haaften-Day, C., Shen, Y., Xu, F., Yu, Y., Berchuck, A., Havrilesky, L.J., et al. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma. Cancer 92 (2001), 2837–2844.
6. [6] Ozols, R.F., Bundy, B.N., Greer, B.E., Fowler, J.M., Clarke-Pearson, D., Burger, R.A., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 (2003), 3194–3200.
7. [7] Kinose, Y., Sawada, K., Nakamura, K., Kimura, T., The role of microRNAs in ovarian cancer. BioMed Res. Int., 2014, 2014.
8. [8] Prahm, G.W., Høgdall, C., Høgdall, E., Current status on microRNAs as biomarkers for ovarian cancer. Apmis, 2016.
9. [9] Hemmatzadeh, M., Mohammadi, H., Jadidi-Niaragh, F., Asghari, F., Yousefi, M., The role of oncomirs in the pathogenesis and treatment of breast cancer. Biomed. Pharmacother. 78 (2016), 129–139.
10. [10] Hemmatzadeh, M., Mohammadi, H., Karimi, M., Musavishenas, M.H., Baradaran, B., Differential role of microRNAs in the pathogenesis and treatment of Esophageal cancer. Biomed. Pharmacother. 82 (2016), 509–519.
11. [11] Calin, G.A., Dumitru, C.D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. 99 (2002), 15524–15529.
12. [12] Zhang, W., Dahlberg, J.E., Tam, W., MicroRNAs in tumorigenesis: a primer. Am. J. Pathol. 171 (2007), 728–738.
13. [13] Pal, M.K., Jaiswar, S.P., Dwivedi, V.N., Tripathi, A.K., Dwivedi, A., Sankhwar, P., MicroRNA: a new and promising potential biomarker for diagnosis and prognosis of ovarian cancer. Cancer Biol. Med., 12, 2015, 328.
14. [14] Dahiya, N., Morin, P.J., MicroRNAs in ovarian carcinomas. Endocr. Relat. Cancer 17 (2010), F77–F89.
15. [15] Lewis, B.P., Shih, I.-h., Jones-Rhoades, M.W., Bartel, D.P., Burge, C.B., Prediction of mammalian microRNA targets. Cell 115 (2003), 787–798.
16. [16] Johnson, S.M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., et al. RAS is regulated by the let-7 microRNA family. Cell 120 (2005), 635–647.
17. [17] Kumar, M.S., Erkeland, S.J., Pester, R.E., Chen, C.Y., Ebert, M.S., Sharp, P.A., et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc. Natl. Acad. Sci. 105 (2008), 3903–3908.
18. [18] Cimmino, A., Calin, G.A., Fabbri, M., Iorio, M.V., Ferracin, M., Shimizu, M., et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 13944–13949.
19. [19] le Sage, C., Nagel, R., Egan, D.A., Schrier, M., Mesman, E., Mangiola, A., et al. Regulation of the p27Kip1 tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 26 (2007), 3699–3708.
20. [20] Chang, T.-C., Wentzel, E.A., Kent, O.A., Ramachandran, K., Mullendore, M., Lee, K.H., et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell 26 (2007), 745–752.
21. [21] Hermeking, H., p53 Enters the microRNA world. Cancer Cell 12 (2007), 414–418.
22. [22] Wightman, B., Ha, I., Ruvkun, G., Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75 (1993), 855–862.
23. [23] Perron, M.P., Provost, P., Protein interactions and complexes in human microRNA biogenesis and function. ABBV Front Biosci., 13, 2008, 2537.
24. [24] Rajewsky, N., MicroRNA target predictions in animals. Nat. Genet. 38 (2006), S8–S13.
25. [25] Liu, W., Mao, S.-Y., Zhu, W.-Y., Impact of tiny miRNAs on cancers. World J. Gastroenterol., 13, 2007, 497.
26. [26] Cullen, B.R., Transcription and processing of human microRNA precursors. Mol. Cell 16 (2004), 861–865.
27. [27] Griffiths-Jones, S., Saini, H.K., van Dongen, S., Enright, A.J., miRBase: tools for microRNA genomics. Nucl. Acids Res. 36 (2008), D154–D158.
28. [28] Zhang, L., Huang, J., Yang, N., Greshock, J., Megraw, M.S., Giannakakis, A., et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc. Natl. Acad. Sci. 103 (2006), 9136–9141.
29. [29] Iorio, M.V., Visone, R., Di Leva, G., Donati, V., Petrocca, F., Casalini, P., et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 67 (2007), 8699–8707.
30. [30] Cho, W.C., MicroRNAs: potential biomarkers for cancer diagnosis prognosis and targets for therapy. Int. J. Biochem. Cell Biol. 42 (2010), 1273–1281.
31. [31] Cho, W.C., Great potential of miRNAs as predictive and prognostic markers for cancer. Expert Rev. Mol. Diagn. 12 (2012), 315–318.
32. [32] Zhang, L., Volinia, S., Bonome, T., Calin, G.A., Greshock, J., Yang, N., et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc. Natl. Acad. Sci. 105 (2008), 7004–7009.
33. [33] Saito, Y., Liang, G., Egger, G., Friedman, J.M., Chuang, J.C., Coetzee, G.A., et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9 (2006), 435–443.
34. [34] Calura, E., Fruscio, R., Paracchini, L., Bignotti, E., Ravaggi, A., Martini, P., et al. miRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities. Clin. Cancer Res. 19 (2013), 4114–4123.
35. [35] Nam, E.J., Yoon, H., Kim, S.W., Kim, H., Kim, Y.T., Kim, J.H., et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin. Cancer Res. 14 (2008), 2690–2695.
36. [36] Vang, S., Wu, H.-T., Fischer, A., Miller, D.H., MacLaughlan, S., Douglass, E., et al. Identification of ovarian cancer metastatic miRNAs. PLoS One, 8, 2013, e58226.
37. [37] C.G.A.R. Network, Integrated genomic analyses of ovarian carcinoma. Nature 474 (2011), 609–615.
38. [38] Yang, D., Sun, Y., Hu, L., Zheng, H., Ji, P., Pecot, C.V., et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell 23 (2013), 186–199.
39. [39] Yang, H., Kong, W., He, L., Zhao, J.-J., O'Donnell, J.D., Wang, J., et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 68 (2008), 425–433.
40. [40] Shell, S., Park, S.-M., Radjabi, A.R., Schickel, R., Kistner, E.O., Jewell, D.A., et al. Let-7 expression defines two differentiation stages of cancer. Proc. Natl. Acad. Sci. 104 (2007), 11400–11405.
41. [41] Roush, S., Slack, F.J., The let-7 family of microRNAs. Trends Cell Biol. 18 (2008), 505–516.
42. [42] Yang, N., Kaur, S., Volinia, S., Greshock, J., Lassus, H., Hasegawa, K., et al. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res. 68 (2008), 10307–10314.
43. [43] Büssing, I., Slack, F.J., Großhans, H., let-7 microRNAs in development, stem cells and cancer. Trends Mol. Med. 14 (2008), 400–409.
44. [44] Prahm, K.P., Karlsen, M.A., Høgdall, E., Scheller, N.M., Lundvall, L., Nedergaard, L., et al. The prognostic value of dividing epithelial ovarian cancer into type I and type II tumors based on pathologic characteristics. Gynecol. Oncol. 136 (2015), 205–211.
45. [45] Hu, X., Macdonald, D.M., Huettner, P.C., Feng, Z., El Naqa, I.M., Schwarz, J.K., et al. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol. Oncol. 114 (2009), 457–464.
46. [46] Eitan, R., Kushnir, M., Lithwick-Yanai, G., David, M.B., Hoshen, M., Glezerman, M., et al. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol. Oncol. 114 (2009), 253–259.
47. [47] Mateescu, B., Batista, L., Cardon, M., Gruosso, T., de Feraudy, Y., Mariani, O., et al. miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat. Med. 17 (2011), 1627–1635.
48. [48] Laios, A., O'Toole, S., Flavin, R., Martin, C., Kelly, L., Ring, M., et al. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol. Cancer, 7, 2008, 1.
49. [49] Lee, H., Park, C.S., Deftereos, G., Morihara, J., Stern, J.E., Hawes, S.E., et al. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features. World J. Surg. Oncol., 10, 2012, 1.
50. [50] Lee, C.-H., Subramanian, S., Beck, A.H., Espinosa, I., Senz, J., Zhu, S.X., et al. MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. PLoS One, 4, 2009, e7314.
51. [51] Corney, D.C., Hwang, C.-I., Matoso, A., Vogt, M., Flesken-Nikitin, A., Godwin, A.K., et al. Frequent downregulation of miR-34 family in human ovarian cancers. Clin. Cancer Res. 16 (2010), 1119–1128.
52. [52] Kim, T.H., Kim, Y.K., Kwon, Y., Heo, J.H., Kang, H., Kim, G., et al. Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours. Histopathology 57 (2010), 734–743.
53. [53] Wan, W.-N., Zhang, Y.-X., Wang, X.-M., Liu, Y.-J., Zhang, Y.-Q., Que, Y.-H., et al. ATAD2 is highly expressed in ovarian carcinomas and indicates poor prognosis. Asian Pac. J. Cancer Prev. 15 (2014), 2777–2783.
54. [54] Xu, Y.-Z., Xi, Q.-H., Ge, W.-L., Zhang, X.-Q., Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer. Asian Pac. J. Cancer Prev. 14 (2013), 1057–1060.
55. [55] Hong, F., Li, Y., Xu, Y., Zhu, L., Prognostic significance of serum microRNA-221 expression in human epithelial ovarian cancer. J. Int. Med. Res., 2013 0300060513475759.
56. [56] Marchini, S., Cavalieri, D., Fruscio, R., Calura, E., Garavaglia, D., Nerini, I.F., et al. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol. 12 (2011), 273–285.
57. [57] Wang, S., Zhao, X., Wang, J., Wen, Y., Zhang, L., Wang, D., et al. Upregulation of microRNA-203 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer. Med. Oncol. 30 (2013), 1–7.
58. [58] Chao, A., Lin, C., Lee, Y., Tsai, C., Wei, P., Hsueh, S., et al. Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2. Oncogene 31 (2012), 764–775.
59. [59] Liang, H., Jiang, Z., Xie, G., Lu, Y., Serum microRNA-145 as a novel biomarker in human ovarian cancer. Tumor Biol. 36 (2015), 5305–5313.
60. [60] Wyman, S.K., Parkin, R.K., Mitchell, P.S., Fritz, B.R., O'Briant, K., Godwin, A.K., et al. Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One, 4, 2009, e5311.
61. [61] Resnick, K.E., Alder, H., Hagan, J.P., Richardson, D.L., Croce, C.M., Cohn, D.E., The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol. Oncol. 112 (2009), 55–59.
62. [62] Häusler, S., Keller, A., Chandran, P., Ziegler, K., Zipp, K., Heuer, S., et al. Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Br. J. Cancer 103 (2010), 693–700.
63. [63] Kan, C.W., Hahn, M.A., Gard, G.B., Maidens, J., Huh, J.Y., Marsh, D.J., et al. Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer, 12, 2012, 1.
64. [64] Chung, Y.-W., Bae, H.-S., Song, J.-Y., Lee, J.K., Lee, N.W., Kim, T., et al. Detection of microRNA as novel biomarkers of epithelial ovarian cancer from the serum of ovarian cancer patient. Int. J. Gynecol. Cancer 23 (2013), 673–679.
65. [65] Suryawanshi, S., Vlad, A.M., Lin, H.-M., Mantia-Smaldone, G., Laskey, R., Lee, M., et al. Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer. Clin. Cancer Res. 19 (2013), 1213–1224.
66. [66] Zheng, H., Zhang, L., Zhao, Y., Yang, D., Song, F., Wen, Y., et al. Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS One, 8, 2013, e77853.
67. [67] Taylor, D.D., Gercel-Taylor, C., MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 110 (2008), 13–21.
68. [68] Peter, M.E., Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle 8 (2009), 843–852.
69. [69] Wang, X., Cao, L., Wang, Y., Wang, X., Liu, N., You, Y., Regulation of let-7 and its target oncogenes (Review). Oncol. Lett. 3 (2012), 955–960.
70. [70] A. Parikh, C., Lee, P., Joseph, S., Marchini, A., Baccarini, V. Kolev, et al. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial–mesenchymal transition. Nat. Commun., 5, 2014.
71. [71] Corney, D.C., Flesken-Nikitin, A., Godwin, A.K., Wang, W., Nikitin, A.Y., MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 67 (2007), 8433–8438.
72. [72] Calura, E., Martini, P., Sales, G., Beltrame, L., Chiorino, G., D'Incalci, M., et al. Wiring miRNAs to pathways: a topological approach to integrate miRNA and mRNA expression profiles. Nucl. Acids Res., 42, 2014, e96.
73. [73] Gregory, P.A., Bert, A.G., Paterson, E.L., Barry, S.C., Tsykin, A., Farshid, G., et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 10 (2008), 593–601.
74. [74] Korpal, M., Lee, E.S., Hu, G., Kang, Y., The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 283 (2008), 14910–14914.
75. [75] Kim, N.H., Kim, H.S., Li, X.-Y., Lee, I., Choi, H.-S., Kang, S.E., et al. A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial–mesenchymal transition. J. Cell Biol. 195 (2011), 417–433.
76. [76] Lou, Y., Yang, X., Wang, F., Cui, Z., Huang, Y., MicroRNA-21 promotes the cell proliferation, invasion and migration abilities in ovarian epithelial carcinomas through inhibiting the expression of PTEN protein. Int. J. Mol. Med., 26, 2010, 819.
77. [77] Medina, R., Zaidi, S.K., Liu, C.-G., Stein, J.L., Croce, C.M., Stein, G.S., MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res. 68 (2008), 2773–2780.
78. [78] Weinberg, L.E., Rodriguez, G., Hurteau, J.A., The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer. J. Surg. Oncol. 101 (2010), 334–343.
79. [79] Sorrentino, A., Liu, C.-G., Addario, A., Peschle, C., Scambia, G., Ferlini, C., Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol. Oncol. 111 (2008), 478–486.
80. [80] Lu, L., Schwartz, P., Scarampi, L., Rutherford, T., Canuto, E.M., Yu, H., et al. MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management. Gynecol. Oncol. 122 (2011), 366–371.
81. [81] Vecchione, A., Belletti, B., Lovat, F., Volinia, S., Chiappetta, G., Giglio, S., et al. A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc. Natl. Acad. Sci. 110 (2013), 9845–9850.
82. [82] Di Leva, G., Garofalo, M., Croce, C.M., MicroRNAs in cancer. Annu. Rev. Pathol., 9, 2014, 287.
83. [83] Li, Z., Rana, T.M., Therapeutic targeting of microRNAs: current status and future challenges. Nat. Rev. Drug Discov. 13 (2014), 622–638.
84. [84] Wu, Q., Guo, R., Lin, M., Zhou, B., Wang, Y., MicroRNA-200a inhibits CD133/1+ ovarian cancer stem cells migration and invasion by targeting E-cadherin repressor ZEB2. Gynecol. Oncol. 122 (2011), 149–154.
85. [85] Chen, D., Zhang, Y., Wang, J., Chen, J., Yang, C., Cai, K., et al. MicroRNA-200c overexpression inhibits tumorigenicity and metastasis of CD117+ CD44+ ovarian cancer stem cells by regulating epithelial-mesenchymal transition. J. Ovar. Res., 6, 2013, 1.
86. [86] Pecot, C.V., Rupaimoole, R., Yang, D., Akbani, R., Ivan, C., Lu, C., et al. Tumour angiogenesis regulation by the miR-200 family. Nat. Commun., 4, 2013.
87. [87] Chen, R., Alvero, A., Silasi, D., Kelly, M., Fest, S., Visintin, I., et al. Regulation of IKKβ by miR-199a affects NF-(B activity in ovarian cancer cells. Oncogene 27 (2008), 4712–4723.
88. [88] Yin, G., Chen, R., Alvero, A.B., Fu, H.-H., Holmberg, J., Glackin, C., et al. TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene 29 (2010), 3545–3553.
89. [89] Cheng, W., Liu, T., Wan, X., Gao, Y., Wang, H., MicroRNA‐199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer‐initiating cells. FEBS J. 279 (2012), 2047–2059.
90. [90] Liu, M.X., Siu, M.K., Liu, S.S., Yam, J.W., Ngan, H.Y., Chan, D.W., Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer. Oncotarget, 5, 2014, 944.
91. [91] Joshi, H.P., Subramanian, I.V., Schnettler, E.K., Ghosh, G., Rupaimoole, R., Evans, C., et al. Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis. Proc. Natl. Acad. Sci. 111 (2014), 5331–5336.
92. [92] Park, S.-M., Shell, S., Radjabi, A.R., Schickel, R., Feig, C., Boyerinas, B., et al. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle 6 (2007), 2585–2590.
93. [93] Tang, Z., Ow, G.S., Thiery, J.P., Ivshina, A.V., Kuznetsov, V.A., Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma. Int. J. Cancer 134 (2014), 306–318.
94. [94] Sawada, K., Mitra, A.K., Radjabi, A.R., Bhaskar, V., Kistner, E.O., Tretiakova, M., et al. Loss of E-cadherin promotes ovarian cancer metastasis via α5-integrin, which is a therapeutic target. Cancer Res. 68 (2008), 2329–2339.
95. [95] Ohyagi-Hara, C., Sawada, K., Kamiura, S., Tomita, Y., Isobe, A., Hashimoto, K., et al. miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin α5 expression. Am. J. Pathol. 182 (2013), 1876–1889.
96. [96] Creighton, C.J., Fountain, M.D., Yu, Z., Nagaraja, A.K., Zhu, H., Khan, M., et al. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Res. 70 (2010), 1906–1915.
97. [97] Nishimura, M., Jung, E.-J., Shah, M.Y., Lu, C., Spizzo, R., Shimizu, M., et al. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov. 3 (2013), 1302–1315.
98. [98] Chen, D., Wang, J., Zhang, Y., Chen, J., Yang, C., Cao, W., et al. Effect of down-regulated transcriptional repressor ZEB1 on the epithelial-mesenchymal transition of ovarian cancer cells. Int. J. Gynecol. Cancer 23 (2013), 1357–1366.
99. [99] Lu, Y.-m., Shang, C., Ou, Y.-l., Yin, D., Li, Y.-N., Li, X., et al. miR-200c modulates ovarian cancer cell metastasis potential by targeting zinc finger E-box-binding homeobox 2 (ZEB2) expression. Med. Oncol. 31 (2014), 1–11.
100. [100] Van Jaarsveld, M., Helleman, J., Boersma, A., Van Kuijk, P., Van Ijcken, W., Despierre, E., et al. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene 32 (2013), 4284–4293.
101. [101] Cai, J., Yang, C., Yang, Q., Ding, H., Jia, J., Guo, J., et al. Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin. Oncogenesis, 2, 2013, e75.